Tirzepatide

FDA Approved

Tirzepatide (LY3298176)

Aliases
Mounjaro, Zepbound, LY3298176
Administration
Subcutaneous injection (once weekly)

Overview

First-in-class dual GIP and GLP-1 receptor agonist. SURMOUNT trials demonstrated up to 22.5% body weight reduction — the highest of any pharmacological agent studied for obesity.

Treatments studied

Treatment categories

Cardiovascular disease

Improves several cardiometabolic risk factors, including blood pressure and cholesterol, alongside weight loss.

Fatty liver disease (NAFLD)

Reduces liver fat through its combined effects on insulin sensitivity and body weight.

Obesity / weight management

Simultaneously suppresses appetite and slows digestion via dual GIP and GLP-1 receptor activation.

Sleep apnea

Weight loss driven by the compound reduces the excess tissue contributing to airway obstruction during sleep.

Type 2 diabetes

Stimulates glucose-dependent insulin release while improving the body's overall insulin sensitivity.